Preclinical toxicological study of the new enterosorbent noolit
Karpova, G.V.; Borodin, I.I.; Rachkovskaia, L.N.; Fomina, T.I.; Vetoshkina, T.V.; Abramova, E.V.; Novoselova, T.I.
Eksperimental'naia i Klinicheskaia Farmakologiia 69(3): 63-67
2006
ISSN/ISBN: 0869-2092 PMID: 16878504 Document Number: 598284
The safety of the new enterosorbent noolit has been evaluated within the framework of its preclinical characterization. Single introduction of noolit to rats and mice (females and males) in maximum doses for intragastric administration (5.0 - 20.0 g/kg) does not lead to the loss of experimental animals. Single administration of large doses (5 - 40 times the effictive dose) can reduce the growth of the total body weight and lead to the development of nonlethal pathological changes of hemopoietic organs, which is manifested by a weak regenerative anemia (5 % of cases); neutrophile, cosinophile, and basophile leukocytosis (3 % of cases); and a decrease in the glucose level in blood serum. In chronic experiments on rabbits, the administration of noolit for 3 months in a dose of 0.5 and 2.0 g/kg (2 and 8 times that recommended for humans) did not reveal any toxic action on the functional and morphological state of the main systems and organs (blood, liver, kidneys, lungs, heart, gastrointestinal tract, sex organs, etc.).